Status:
ACTIVE_NOT_RECRUITING
Determining Molecular Drivers of Radiation Dermatitis
Lead Sponsor:
Mayo Clinic
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study is being conducted to address key gaps in current knowledge and set the stage for rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure to radiation ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients receiving standard-of-care postoperative radiation therapy (2-2.7 Gy per fraction) to the breast and/or chest wall for breast cancer treatment.
- Tissue diagnosis of breast cancer.
- Age \> 18 years
- Signed informed consent.
- Complete blood count within normal limits within the preceding 2 weeks.
- Exclusion criteria:
- Induction chemotherapy or biologic therapy
- Concurrent chemotherapy or biologic therapy
- Autoimmune disease with skin manifestations - psoriasis, dermatomyositis, scleroderma, eczema, polymyositis
- Allergy to lidocaine anesthesia
- Known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding disorders, vitamin C or K deficiency, thrombocytopenia)
- History of keloids or easy scarring
Exclusion
Key Trial Info
Start Date :
February 21 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04764682
Start Date
February 21 2021
End Date
February 1 2026
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Jacksonville, Florida, United States, 32224